Full Press Release Details
Meiji Holdings Co., Ltd.
Name of Representative:
Kazuo Kawamura, CEO, President and Representative Director
2269, Prime Market, Tokyo Stock Exchange
Submitted New Drug Application to Manufacture
and Market ARCT-154,
Next Generation mRNA Vaccine against COVID-19,
Meiji Holdings Co., Ltd. announces that its subsidiary,
Meiji Seika Pharma Co., Ltd., submitted a New Drug Application to manufacture and market ARCT-154 for primary immunization to prevent
COVID-19 in adults (two doses of ARCT-154) in Japan. ARCT-154, a next generation mRNA vaccine against COVID-19, was developed by Arcturus
Therapeutics Inc*1 and in April, Meiji obtained exclusive rights to distribute ARCT-154 in Japan from CSL Seqirus.*2
ARCT-154 uses next-generation mRNA technology which
offers strong immune response, a favorable tolerability profile and the potential for extended duration of protection while using lower
doses of mRNA compared to existing mRNA vaccines.
Meiji Seika Pharma submitted an NDA for primary immunization
of ARCT-154 based on results of a Phase III clinical trial (NCT05012943) conducted in Vietnam involving more than 16,000 subjects. The
trial evaluated safety, immunogenicity and efficacy of primary immunization of ARCT-154 and the results met its primary endpoint of prevention
of COVID-19. Meiji Seika Pharma has been conducting a Phase III study in Japan since December 13, 2022, to evaluate the safety and immunogenicity
of ARCT-154 as a booster against COVID-19, and completed enrollment in February 2023.
Under the terms of an agreement with CSL Seqirus,
Meiji Seika Pharma will be responsible for obtaining regulatory approval, and for distribution, sales and marketing of ARCT-154 in Japan.
Meiji Seika Pharma is collaborating with ARCALIS,
Inc.*3 to establish an integrated mRNA vaccine manufacturing from drug substance to drug product in Japan. ARCALIS is building
a manufacturing facility in Minami-soma City, Fukushima Prefecture.
Meiji Seika Pharma is working to supply ARCT-154
in Japan as soon as possible following approval. If approved, ARCT-154 will become a new vaccination option against COVID-19. The impact
on the consolidated financial results forecast for the fiscal year ending March 31, 2024, has not been determined at this time. We will
closely examine the situation and disclose the impact as soon as it is recognized.
Disclaimer: This English translation is prepared
for the readers' convenience. When there are any discrepancies between the original Japanese version and English translation version,
the original Japanese version always prevails.